Entropy Neurodynamics (ENP) Short Interest
Entropy Neurodynamics (ASX:ENP) had 0.00% of shares reported as short positions as of 24 Aug 2026, representing 6 shares. Entropy Neurodynamics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Entropy Neurodynamics
Entropy Neurodynamics is an Australian biotechnology company focused on developing novel therapies for neurological and psychiatric disorders. They leverage innovative approaches in drug development, aiming to address unmet needs in mental health and improve patient outcomes. The company is listed on the ASX and seeks to create value through its research and development pipeline.
Short position
Entropy Neurodynamics (ASX:ENP) has 0.00% of its shares on issue reported as short positions as of 24 Aug 2026, or about 6 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. ENP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4ENP intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Entropy Neurodynamics
Latest ENP news
All newsAbout
website
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss ENP
Start a research thread or post the first pulse update